Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download NUCYNTA ER Drug Profile, 2023 PDF full book. Access full book title NUCYNTA ER Drug Profile, 2023 by DrugPatentWatch. Download full books in PDF and EPUB format.
Author: Charlotte Allerton Publisher: Royal Society of Chemistry ISBN: 1849736456 Category : Medical Languages : en Pages : 428
Book Description
This book presents a contemporary review of the field of pain therapeutics, including the historical medicines which still dominate standard of care treatments, as well as the new mechanisms and combinations/reformulations that have dominated the regulatory approvals over the last decade. In addition this book provides a deep review of the key biological mechanisms currently under investigation for their utility into the treatment of pain, such as ion channels, opiates and others. Additional discussion highlights the current challenges of pain research, covering a range of topics from difficulties in identifying new targets and pre-clinical models to the current regulatory and commercial challenges. This background sets the scene for recent scientific developments in pain research, such as the drive for genetic validation of targets and the derivation of human cell platforms from stem cells. Finally, the book covers the discovery and development stories of two pain products approved in the last decade. These case studies for Lyrica and the Butrans patch, will give insight into the discovery and development challenges and successes for both an oral and non-oral product.
Author: Michael J. Barratt Publisher: John Wiley & Sons ISBN: 0470878274 Category : Medical Languages : en Pages : 499
Book Description
The how's and why's of successful drug repositioning Drug repositioning, also known as drug reprofiling or repurposing, has become an increasingly important part of the drug development process. This book examines the business, technical, scientific, and operational challenges and opportunities that drug repositioning offers. Readers will learn how to perform the latest experimental and computational methods that support drug repositioning, and detailed case studies throughout the book demonstrate how these methods fit within the context of a comprehensive drug repositioning strategy. Drug Repositioning is divided into three parts: Part 1, Drug Repositioning: Business Case, Strategies, and Operational Considerations, examines the medical and commercial drivers underpinning the quest to reposition existing drugs, guiding readers through the key strategic, technical, operational, and regulatory decisions needed for successful drug repositioning programs. Part 2, Application of Technology Platforms to Uncover New Indications and Repurpose Existing Drugs, sets forth computational-based strategies, tools, and databases that have been designed for repositioning studies, screening approaches, including combinations of existing drugs, and a look at the development of chemically modified analogs of approved agents. Part 3, Academic and Non-Profit Initiatives & the Role of Alliances in the Drug Repositioning Industry, explores current investigations for repositioning drugs to treat rare and neglected diseases, which are frequently overlooked by for-profit pharmaceutical companies due to their lack of commercial return. The book's appendix provides valuable resources for drug repositioning researchers, including information on drug repositioning and reformulation companies, databases, government resources and organizations, regulatory agencies, and drug repositioning initiatives from academia and non-profits. With this book as their guide, students and pharmaceutical researchers can learn how to use drug repositioning techniques to extend the lifespan and applications of existing drugs as well as maximize the return on investment in drug research and development.